RT Journal Article
SR Electronic
T1 The Role of Functional Dopamine-Transporter SPECT Imaging in Parkinsonian Syndromes, Part 2
JF American Journal of Neuroradiology
JO Am. J. Neuroradiol.
FD American Society of Neuroradiology
SP 236
OP 244
DO 10.3174/ajnr.A3971
VO 36
IS 2
A1 T.C. Booth
A1 M. Nathan
A1 A.D. Waldman
A1 A.-M. Quigley
A1 A.H. Schapira
A1 J. Buscombe
YR 2015
UL http://www.ajnr.org/content/36/2/236.abstract
AB SUMMARY: The functional imaging technique most widely used in European clinics to differentiate a true parkinsonian syndrome from vascular parkinsonism, drug-induced changes, or essential tremor is dopamine-transporter SPECT. This technique commonly reports dopamine-transporter function, with decreasing striatal uptake demonstrating increasingly severe disease. The strength of dopamine-transporter SPECT is that nigrostriatal degeneration is observed in both clinically inconclusive parkinsonism and early, even premotor, disease. In this clinical review (Part 2), we present the dopamine-transporter SPECT findings in a variety of neurodegenerative diseases, including multiple system atrophy, progressive supranuclear palsy, corticobasal degeneration, and dementia with Lewy bodies. The findings in vascular parkinsonism, drug-induced parkinsonism, and essential tremor are also described. It is hoped that this technique will be the forerunner of a range of routinely used, process-specific ligands that can identify early degenerative disease and subsequently guide disease-modifying interventions. CBDcorticobasal degenerationDaTdopamine transporters18Ffluorine 18IBF123I-(S)-5-iodo-7-N-{(1-ethyl-2-pyrrolidinyl) methyl}carboxamido-2,3-dihydrobenzofuranIBZM123I-S-(K)-N-[(1-ethyl-2-pyrrolidinyl)methyl]-2-hydroxy-3-iodo-6-methoxybenzamide123I-FP-CIT123I-ioflupane (N-ω-fluoropropyl-β CIT)MSAmultiple system atrophyMSA-Ppatients with multiple system atrophy with predominant parkinsonismPSPprogressive supranuclear palsy